Q-omics provides the consensus-scored KCNS3 profile across patient tissues and cancer cell-line models. KCNS3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KCNS3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KCNS3 RNA expression shows 17,795 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where KCNS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNS3 survival associations across molecular data types. KCNS3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNS3 RNA expression–survival associations across cancer types. High KCNS3 expression shows unfavorable associations in ACC, KICH, KIRP and THCA, but favorable associations in UCS and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for KCNS3 RNA expression.
This table summarizes KCNS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNS3 shows lower tumor expression in KICH and higher tumor expression in KIRC, THCA, HNSC, KIRP and BLCA. The KIRC box plot shows higher KCNS3 RNA expression in tumor versus normal tissue (log2 FC = +1.004, t-test p < 0.001).
This table shows molecular features associated with KCNS3 in patient tissues and cancer cell lines. In patient samples, KCNS3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
